Gene:
CACNA1C
calcium channel, voltage-dependent, L type, alpha 1C subunit

Overview

Alternate Names: DHPR, alpha-1 subunit; calcium channel, L type, alpha 1 polypeptide, isoform 1, cardic muscle; calcium channel, cardic dihydropyridine-sensitive, alpha-1 subunit; voltage-gated L-type calcium channel Cav1.2 alpha 1 subunit, splice variant 10*; voltage-gated calcium channel alpha subunit Cav1.2
Alternate Symbols: CACH2; CACN2; CACNL1A1; CCHL1A1; CaV1.2; Cav1.2; MGC120730; TS
PharmGKB Accession Id: PA83

Details

Cytogenetic Location: chr12 : p13.33
GP mRNA Boundary: chr12 : 2032725 - 2672369
GP Gene Boundary: chr12 : 2022725 - 2675369
Strand: plus
Product Name: DHPR, alpha-1 subunit, calcium channel, L type, alpha 1 polypeptide, isoform 1, cardic muscle, calcium channel, cardic dihydropyridine-sensitive, alpha-1 subunit, calcium channel, voltage-dependent, L type, alpha 1C subunit, voltage-dependent L-type calcium channel alpha 1C subunit, voltage-gated calcium channel alpha subunit Cav1.2
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Annotations (Curated Annotation)

  1. rs1006737 at chr12:2215556 in CACNA1C
    A genome-wide association analysis study in 4,387 cases and 6,209 controls identified a strong association of this variant in the CACNA1C gene with bipolar disorder.
    Related Diseases:
    Bipolar Disorder
    Evidence:
    PMID:18711365
  2. rs216013 at chr12:2599893 in CACNA1C
    This intronic variant in the membrane calcium-channel gene CACNA1C was correlated with warfarin dose (p = 9.2 × 10−5) in the index population (n = 181) from a GWAS study of white patients undergoing anticoagulation therapy. Combined analysis of the index and replication populations (n = 374) yielded a p value of 8.6 × 10−7. "However, this variant did not reach established significance threshold independently in the replication population (P = .002), nor did it achieve significance after multiple testing correction in multivariate modeling (uncorrected P = .003)".
    Related Drugs:
    warfarin
    Evidence:
    PMID:18535201
  3. rs1051375 at chr12:2659140 in CACNA1C
    In a case-control study (258 cases; 774 controls) performed in patients residing in the mainland U.S. or Puerto Rico and who had hypertension and stable coronary artery disease, this SNP was found to be related to primary outcome of atenolol vs. verapamil SR - based treatment. AA genotype was associated with 46% reduction in primary outcome for patients on verapamil SR-based treatment compared to atenolol-based treatment (odds ratio 0.54; 95% CI 0.32 to 0.92), AG genotype showed no difference in primary outcome between the two strategies (odds ratio 1.47; 95% CI 0.86 to 2.53), and GG subjects had more than 4 fold increased risk of primary outcome on verapamil SR-based treatment as opposed to atenolol-based treatment (odds ratio 4.59; 95% CI 1.67 to 12.67). Study size: 258 cases; 774 controls. Study population/ethnicity: subjects residing in the mainland U.S. or Puerto Rico. Type of association: CO; GN; PD. Significance metric(s): P value: P=0.0001.
    Related Drugs:
    atenolol, Beta Blocking Agents, calcium channel blockers, verapamil
    Related Diseases:
    Coronary Artery Disease, Death, Death, Sudden, Cardiac, Hypertension, Myocardial Infarction, Stroke
    Evidence:
    PMID:20031608

Non-Curated Annotations (Non-Curated Annotation)

  1. rs216013 at chr12:2599893 in CACNA1C
    GWAS results: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose (Initial Sample Size: 181 individuals; Replication Sample Size: 374 individuals). This variant is associated with Warfarin maintenance dose.
    Related Drugs:
    warfarin
    Evidence:
    PMID:18535201
    http://www.genome.gov/gwastudies/
Variant names are different names that have been used in the literature and other resources to refer to the same variant. Non-curated variant information is accumulated solely by computational methods and has not been verified by the scientific staff at PharmGKB.

Non-Curated Information

A list of non-curated publications that mention this gene along with other genes is available.

Curated Information

The following drugs are in curated knowledge about this gene.

  Drug Class Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
antiarrhythmics, class i and iii
  •   
  • PD
  •   
  • FA
  •   
Publications, Pathways
Phenotype data available No genotype data Literature annotations available Not annotated
Beta Blocking Agents
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
calcium channel blockers
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
  Drug Relationship Evidence
Phenotype data available Genotype Data Available Literature annotations available Not annotated
amiodarone
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
amlodipine
  • CO
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
arsenic trioxide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
atenolol
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data No literature annotations Not annotated
chlorpropamide
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
cisapride
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
disopyramide
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
dofetilide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
droperidol
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
felodipine
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
flecainide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
gliclazide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
glimepiride
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
glipizide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
halofantrine
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
haloperidol
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
ibutilide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
isradipine
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
lidocaine
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
mesoridazine
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
methadone
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
mexiletine
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
nateglinide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
nicardipine
  •   
  • PD
  •   
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
nicotine
  •   
  • PD
  •   
  • FA
  •   
Publications, Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
nifedipine
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
nimodipine
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
nisoldipine
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
nitrendipine
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
pentamidine
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
pimozide
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
procainamide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
propafenone
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
quinidine
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
repaglinide
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
sotalol
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
sparfloxacin
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available No genotype data Literature annotations available Not annotated
thioridazine
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data No literature annotations Not annotated
tocainide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
tolbutamide
  •   
  • PD
  •   
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
verapamil
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
Phenotype data available Genotype Data Available Literature annotations available Not annotated
warfarin
  •   
  •   
  •   
  •   
  •   
Variants

Non-Curated Information

A list of non-curated publications that mention this gene along with other drugs is available.

Curated Information

The following diseases are in curated knowledge about this gene.

  Disease Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
Bipolar Disorder
  •   
  •   
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Coronary Artery Disease
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Death
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Death, Sudden, Cardiac
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Diabetes Mellitus
  •   
  • PD
  •   
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Hypertension
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Myocardial Infarction
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
Phenotype data available No genotype data Literature annotations available Not annotated
Stroke
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Tobacco Use Disorder
  •   
  • PD
  •   
  •   
  •   
Pathways

Non-Curated Information

A list of non-curated publications that mention this gene along with other diseases is available.

Additional Datasets

These datasets are minimally curated and are sorted alphabetically by title.

  1. A chemogenomic approach to drug discovery: focus on cardiovascular diseases

LinkOuts

Common Searches

Non-Curated Publications

A list of non-curated publications that mention this gene is available.

The PharmGKB is financially supported by the NIH/ NIGMS and is managed at Stanford University (U01GM61374).
©2001-2010 PharmGKB.